Click 'Unlock insights' in the navigation menu above to discover more!

Unlocking Insights
in Lung Cancer

LynxCare's comprehensive data asset offers fresh insights into lung cancer, including comorbidity factors, treatment patterns, and staging. With over +7485 estimated patients and 610 endpoints measured, our granular and quality-controlled real-world dataset can unlock invaluable insights into the treatment and prognosis of lung cancer patients, empowering clinicians to make informed decisions.

LC Insight LP

Closing the Gap
The Value of Unstructured Data in the Lung Cancer Pathway

Structured vs Unstructured

Structured data alone only provides part of the picture, missing key nuances. Combining structured data with rich EHR narrative data can improve our understanding of lung cancer pathophysiology, outcomes and characteristics at diagnosis, as evidenced by our data which yielded a higher prevalence of COPD patients of 19.6% vs 12.5% on structured data only.

https://ascopubs.org/doi/full/10.1200/CCI.22.00155 (Unstructured Data Are Superior to Structured Data for Eliciting Quantitative Smoking History From the Electronic Health Record, DOI: 10.1200/CCI.22.00155 JCO Clinical Cancer Informatics no. 7 (2023) e2200155. Published online February 21, 2023.)

RCT vs RWD

During the year following U.S. regulatory approval of PD‐1 inhibitors for treatment of NSCLC, real‐world patients receiving nivolumab or pembrolizumab were older at treatment initiation and more had smoking history relative to clinical trial cohorts. Studies of outcomes in underrepresented subgroups are needed to inform real‐world treatment decisions.

Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5905694/

Real-World Insights into the Patient Journey

By leveraging unstructured data, we can obtain a more comprehensive and accurate view of the patient journey, enabling better decision-making and improved patient care.

Lung Cancer Dataset Insights

Our dataset* provides valuable insights into lung cancer, including but not limited to:

LC dataset insights-2

Note that the estimated patient counts provided (prior to inclusion/exclusion criteria) are specific to our Belgian dataset. Details on the representativeness and diversity of the Belgian dataset for global studies can be found above. The LynxCare datasets continue to expand, encompassing real-world data from hospitals across Europe. Complete the form on the right to gain further details and to discuss your study needs with one of our RWE experts.

Contact us

Unpacking the Data
The Sources Behind Our Insights

  • Patient demographics
  • Vital signs
  • Claims data
  • Biomarkers
  • Medications
  • Tumor staging
  • Active and inactive medical problems
  • Surgical interventions
  • Hospital procedures, visits & hospitalizations
  • In and out of hospital mortality
  • Drug regimens
  • Doses and durations of chemotherapy
  • Lab results
  • Gene expression profiles (PD-L1/EGFR/ALK/..)
  • Molecular-level information
innovation 2_used

The Future of Lung Cancer Therapy
How LynxCare Can Help

Personalized Medicine

With our comprehensive dataset and world-class expertise, LynxCare is well-positioned to help clinicians tailor treatments to specific patient needs, opening up the possibility of personalized medicine for lung cancer. Our data asset provides valuable insights into individual pathways of lung cancer patients, enabling clinicians to make more informed treatment decisions.

Improved Outcomes

Our data asset aims to ultimately improve patient outcomes by providing insights into the clinical pathway of lung cancer patients. By analyzing real-world patient data, our dataset offers a unique perspective on the effectiveness and safety of different treatments. This information can help clinicians make more informed treatment decisions, leading to better outcomes for patients.

Continued Innovation

LynxCare is committed to driving innovation in lung cancer treatment and management. With our world-class expertise in data analysis and interpretation, we aim to continue to provide valuable insights and solutions to healthcare providers and researchers. Our comprehensive dataset offers a wealth of information for life science companies and other stakeholders interested in advancing lung cancer therapy.

Unlock Insights
How Pharma Can Leverage LynxCare's Dataset 

Pharmaceutical companies leverage LynxCare's comprehensive EU dataset to gain insights and develop new treatments.
Our data is particularly useful for:

Unlock Research Questions
Insights for Life Science Companies

Our dataset offers life science companies unparalleled insights into the relationship between specific biomarkers, comorbidities, and treatment outcomes in lung cancer.

Research Question/
Endpoints		 Titration/Dosing Treatment dynamics Incidence & Prevalence Adherence Efficacy Indication split Safety profile
Demographics
Cancer type
Histology
Comorbidities  
Lab results      
Cancer treatment
Hospital visit &
admissions		            
Survival      
Biomarkers
Genetic drivers		            
Outcomes        
Adverse events          
Complications          

Unlock Insights
How Hospitals Can Benefit from a LynxCare Database 

Multi-purpose use of a LynxCare OMOP-CDM NLP-enriched Hospital Database

Improving Patient Care

  • Find more relevant medical information thanks to LynxCare's disease-specific NLP pipeline for a better patient and population understanding

Research & Network Opportunities

  • Initiate or participate in national and international multi-center, multi-country RWE studies
  • Benefit from network of KOLs

Scientific Research

  • Initiate or participate in (pharma- or physician initiated) peer-reviewed (multi-center, multi-country) publications

Increased Clinical Trial Participation

  • More effective patients/cohort selection through clinical NLP, enrolling more patients in clinical trials

Improve your Data Quality

  • Receive feedback on the clinical data quality of your hospital’s database
  • Benefit from data science training provided
narrow patient 2

Patient Insights
More Than Just Numbers

Individualized Care

Our data asset goes beyond just providing numbers and statistics. It offers insights into the individual pathways of lung cancer patients, enabling clinicians to tailor treatments to the specific needs of each patient.

Cross-Disciplinary Collaboration

Our data asset has been used by healthcare providers as well as clinical researchers, enabling cross-disciplinary collaboration and innovation in lung cancer treatment and management, leading to insights useful to compare OS in the real-world vs phase III trials in different treatment line settings.

Impact on Patient Outcomes

Ultimately, our data asset aims to improve the lives of lung cancer patients by providing insights that lead to better clinical outcomes and patient experiences. With our comprehensive dataset, clinicians and researchers can tailor treatments to the real-world patient population, ultimately leading to better outcomes.

Building Trust
Quality Control and Data Freshness

Quality Control

We adhere to strict data quality standards to ensure the accuracy and reliability of our data. Our team of experts verifies and validates data from intake, data processing up till analytics, ensuring consistency and completeness throughout the patient pathway. Each statistic needs to be validated by the individual hospital before delivery.

Data Freshness

Our data is updated regularly to ensure we provide insights based on the latest and most accurate information. Leveraging our HL7-based gateway, our datasets remain fresh with a max of 6-months delay.

OMOP CDM Data Warehouse

Our data is stored in the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM), enabling easy access and integration with other healthcare or research IT solutions. With our well-structured and standardized data storage, our clients can start analyzing the data immediately and efficiently.

narrow data2

World-Class Expertise
The LynxCare Advantage

Representativity

We do our best to ensure representativity by including data from a mix of academic and non-academic centers. This captures the real-world patient and treatment pathway.

Data Experts

Our team of data experts has a combined 50+ years of experience in healthcare data analytics and quality control.

Clinical Experts

We partner with clinical experts in lung cancer and other specialties to ensure our data offers relevant and valuable insights for healthcare professionals.

Hospital Network & Data Access

The hospitals remain in control over their own data. Each RWE request is individually handled following data governance guidelines and timelines in
our master service agreement to accelerate the delivery of insights.

Partnership with the best statistical firms

LynxCare partners with statistical firms who already have a working relationship with the life science company.

Differentiating factors from other NLP providers & established RWD vendors
Differentiating Factors

Size and Granularity

Our data asset contains over 7400 estimated lung cancer treated patients and 610 endpoints measured throughout the patient pathway, offering exceptional granularity for analysis.

Data Quality and Freshness

Our strict data quality standards and regular updates ensure that our dataset is both reliable and up-to-date, providing the most valuable insights for our clients.

Disease-specific NLP

Our NLP is disease-specific. As a result, the data is far more complete compared to other broad NLP vendors.

OMOP-CDM Data Warehouse

Our dataset is stored in the widely-used OMOP-CDM format, enabling our clients to easily integrate our data with other healthcare or research IT solutions.

Fast Data Access

We run projects on databases already built and manage your expectations upfront with a feasibility check for your study protocol. 

*LynxCare datasets concern datasets within the LynxCare's European hospital network. The hospitals are the data controllers. No commitment before site approval on RWE request.